LEXICON PHARMACEUTICALS, INC. (LXRX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
33/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinLXRX / S&P 53.85% / 15.20% |
WinLXRX / S&P 24.09% / 15.00% |
LoseLXRX / S&P -54.55% / 50.40% |
| 2026-Q12/3 |
WinLXRX / S&P 35.65% / -4.33% |
WinLXRX / S&P 1028.74% / 11.30% |
LoseLXRX / S&P -86.27% / 27.70% |
| 2025-Q41/3 |
LoseLXRX / S&P -14.81% / 2.65% |
WinLXRX / S&P 729.91% / 9.00% |
LoseLXRX / S&P -78.13% / 13.40% |
| 2025-Q32/3 |
WinLXRX / S&P 42.11% / 8.12% |
WinLXRX / S&P 795.18% / 4.61% |
LoseLXRX / S&P -74.67% / 13.45% |
| 2025-Q22/3 |
WinLXRX / S&P 106.52% / 10.94% |
WinLXRX / S&P 846.71% / 4.83% |
LoseLXRX / S&P -57.69% / 10.63% |
| 2025-Q11/3 |
LoseLXRX / S&P -37.84% / -4.27% |
WinLXRX / S&P 179.95% / 4.98% |
LoseLXRX / S&P -38.55% / 10.57% |
| 2024-Q41/3 |
LoseLXRX / S&P -52.87% / 2.41% |
WinLXRX / S&P 440.14% / 5.25% |
LoseLXRX / S&P -20.00% / 6.15% |
| 2024-Q31/3 |
LoseLXRX / S&P -6.55% / 5.89% |
WinLXRX / S&P 1066.97% / 5.89% |
LoseLXRX / S&P -2.60% / 6.11% |
| 2024-Q22/3 |
LoseLXRX / S&P -30.00% / 4.28% |
WinLXRX / S&P 1113.06% / 5.38% |
WinLXRX / S&P 13.04% / 5.12% |
| 2024-Q11/3 |
WinLXRX / S&P 56.86% / 10.56% |
LoseLXRX / S&P LXRX unavailable / 5.71% |
LoseLXRX / S&P LXRX unavailable / 5.59% |
| 2023-Q41/3 |
WinLXRX / S&P 40.37% / 11.69% |
LoseLXRX / S&P LXRX unavailable / 6.81% |
LoseLXRX / S&P LXRX unavailable / 7.78% |
| 2023-Q30/3 |
LoseLXRX / S&P -52.40% / -3.27% |
LoseLXRX / S&P LXRX unavailable / 7.52% |
LoseLXRX / S&P LXRX unavailable / -5.03% |
| 2023-Q20/3 |
LoseLXRX / S&P -5.76% / 8.74% |
LoseLXRX / S&P LXRX unavailable / 9.50% |
LoseLXRX / S&P LXRX unavailable / -8.57% |
| 2023-Q11/3 |
WinLXRX / S&P 27.23% / 7.50% |
LoseLXRX / S&P LXRX unavailable / 10.77% |
LoseLXRX / S&P LXRX unavailable / -15.69% |
| 2022-Q40/3 |
LoseLXRX / S&P -20.42% / 7.56% |
LoseLXRX / S&P LXRX unavailable / 11.88% |
LoseLXRX / S&P LXRX unavailable / -17.99% |
| 2022-Q31/3 |
WinLXRX / S&P 29.03% / -4.88% |
LoseLXRX / S&P LXRX unavailable / 13.47% |
LoseLXRX / S&P LXRX unavailable / -1.41% |
| 2022-Q21/3 |
WinLXRX / S&P -11.00% / -16.10% |
LoseLXRX / S&P LXRX unavailable / 13.71% |
LoseLXRX / S&P LXRX unavailable / 11.04% |
| 2022-Q10/3 |
LoseLXRX / S&P -46.95% / -4.60% |
LoseLXRX / S&P LXRX unavailable / 15.97% |
LoseLXRX / S&P LXRX unavailable / 42.23% |
| 2021-Q40/3 |
LoseLXRX / S&P -18.09% / 11.03% |
LoseLXRX / S&P -100.00% / 15.00% |
LoseLXRX / S&P LXRX unavailable / 96.40% |
| 2021-Q31/3 |
WinLXRX / S&P 4.79% / 0.58% |
LoseLXRX / S&P -109.10% / 10.77% |
LoseLXRX / S&P LXRX unavailable / 69.42% |
| 2021-Q20/3 |
LoseLXRX / S&P -21.81% / 8.55% |
LoseLXRX / S&P -19.59% / 6.58% |
LoseLXRX / S&P LXRX unavailable / 51.81% |
| 2021-Q11/3 |
WinLXRX / S&P 71.64% / 6.17% |
LoseLXRX / S&P -21.75% / -1.06% |
LoseLXRX / S&P LXRX unavailable / 7.39% |
| 2020-Q41/3 |
WinLXRX / S&P 137.50% / 12.15% |
LoseLXRX / S&P -27.61% / -3.72% |
LoseLXRX / S&P LXRX unavailable / -33.42% |
| 2020-Q30/3 |
LoseLXRX / S&P -28.00% / 8.93% |
LoseLXRX / S&P -188.87% / -2.04% |
LoseLXRX / S&P LXRX unavailable / -27.10% |
| 2020-Q21/3 |
LoseLXRX / S&P 2.56% / 20.54% |
WinLXRX / S&P 697.17% / -0.46% |
LoseLXRX / S&P LXRX unavailable / -27.11% |
| 2020-Q11/3 |
LoseLXRX / S&P -53.01% / -19.60% |
WinLXRX / S&P 225.35% / 3.47% |
LoseLXRX / S&P LXRX unavailable / -14.75% |
| 2019-Q42/3 |
WinLXRX / S&P 37.87% / 9.07% |
WinLXRX / S&P 21.62% / 5.36% |
LoseLXRX / S&P LXRX unavailable / 2.99% |
| 2019-Q30/3 |
LoseLXRX / S&P -52.15% / 1.70% |
LoseLXRX / S&P -7150.50% / 5.02% |
LoseLXRX / S&P LXRX unavailable / 0.21% |
| 2019-Q21/3 |
WinLXRX / S&P 13.13% / 4.30% |
LoseLXRX / S&P -77.85% / 6.64% |
LoseLXRX / S&P LXRX unavailable / 8.65% |
| 2019-Q10/3 |
LoseLXRX / S&P -16.27% / 13.65% |
LoseLXRX / S&P -49.39% / 8.12% |
LoseLXRX / S&P LXRX unavailable / 14.29% |
| 2018-Q41/3 |
LoseLXRX / S&P -37.77% / -13.52% |
WinLXRX / S&P 59.97% / 9.05% |
LoseLXRX / S&P LXRX unavailable / 18.23% |
| 2018-Q30/3 |
LoseLXRX / S&P -11.08% / 7.71% |
LoseLXRX / S&P -67.95% / 10.21% |
LoseLXRX / S&P LXRX unavailable / 19.06% |
| 2018-Q21/3 |
WinLXRX / S&P 40.02% / 3.43% |
LoseLXRX / S&P -366.04% / 9.03% |
LoseLXRX / S&P LXRX unavailable / 14.46% |
| 2018-Q11/3 |
LoseLXRX / S&P -13.26% / -0.76% |
WinLXRX / S&P 213.11% / 7.68% |
LoseLXRX / S&P LXRX unavailable / 12.46% |
| 2017-Q40/3 |
LoseLXRX / S&P -19.61% / 6.64% |
LoseLXRX / S&P LXRX unavailable / 7.03% |
LoseLXRX / S&P LXRX unavailable / 13.82% |
| 2017-Q30/3 |
LoseLXRX / S&P -25.29% / 4.48% |
LoseLXRX / S&P -106.82% / 5.68% |
LoseLXRX / S&P LXRX unavailable / 17.57% |
| 2017-Q21/3 |
WinLXRX / S&P 14.71% / 3.09% |
LoseLXRX / S&P -103.86% / 4.83% |
LoseLXRX / S&P LXRX unavailable / 17.74% |
| 2017-Q10/3 |
LoseLXRX / S&P 3.69% / 6.07% |
LoseLXRX / S&P -95.88% / 3.67% |
LoseLXRX / S&P LXRX unavailable / 13.32% |
| 2016-Q40/3 |
LoseLXRX / S&P -23.46% / 3.82% |
LoseLXRX / S&P -100.00% / 2.09% |
LoseLXRX / S&P LXRX unavailable / 7.05% |
| 2016-Q32/3 |
WinLXRX / S&P 25.92% / 3.85% |
WinLXRX / S&P 674.61% / 0.20% |
LoseLXRX / S&P LXRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | LXRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 110.91% | 20.78% |
| Annualized return | 110.91% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | LXRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -50.85% | 83.14% |
| Annualized return | -13.24% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | LXRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -83.81% | 319.30% |
| Annualized return | -16.65% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |